tirzepatide cv outcomes trial Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis Tirzepatide and Cardiovascular Outcomes: A
Description
If this describes your situation and youre taking Ozempic, you need to make a clear decision
But after month 5, the tirzepatide patients begin to pull away from the semaglutide patients
Previously trained individuals returning from a long layoff (muscle memory)
Are comfortable with a newer drug still undergoing studies for obesity treatment
